Pharmabiz
 

MorphoSys' AbD Serotec inks 2-year pact with Research Councils UK

Munich, GermanyMonday, October 18, 2010, 16:00 Hrs  [IST]

MorphoSys' research and diagnostic antibodies unit AbD Serotec has signed a two year contract for the supply of custom monoclonal antibodies with Research Councils UK Shared Services Centre Limited. RCUK SSC Ltd has been set up by the seven Research Councils of the UK to provide centralized services to the Research Councils and their institutes in various areas including procurement.

“We are delighted that RCUK SSC Ltd has selected AbD Serotec as one of their service providers of choice,” says Dieter Feger, head of AbD Serotec. "By signing this two year contract, RCUK SSC Ltd confirms their trust in our HuCAL technology and the outstanding service with which AbD Serotec as a division of MorphoSys AG has positioned itself successfully within the biotechnology community.”

Richard Fowles, category manager with RCUK SSC Ltd commented, “We are very pleased to be able to announce that AbD Serotec is to be one of our preferred suppliers of custom monoclonal antibodies. We feel that their great product offering will be of significant benefit to our researchers, especially since the use of their system obviates the use of animals as a source of research antibodies.”

HuCAL stands for Human Combinatorial Antibody Library, a unique collection of billions of recombinant human Fab antibodies which mimics the entire human antibody repertoire. It is an integral part of a sophisticated system that has been proven to deliver highly specific antibodies for all classes of antigens, without the use of animals. HuCAL technology was developed by MorphoSys and is one of the most powerful methods available for generating fully human antibodies for research, diagnostic and therapeutic applications.

MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications.

 
[Close]